As such, CDK4/6 are attractive targets for cancer therapy and several CDK4/6 inhibitors including palbociclib, ribociclib and abemaciclib have been approved for treating patients with advanced or metastatic breast cancer, which demonstrate good clinical results (Laderian and Fojo, 2017). This evidence concerns the gene CDK4 and cancer.